This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

WCLC, Barcelona, Spain 7-10 September 2019

A Phase IIIb, open-label study of afatinib in Caucasian EGFR TKI-naïve patients with EGFRm+ NSCLC: an interim analysis

Filippo De Marinis, Konstantin K Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi, Gyula Ostoros, Simona Rizzato, Guzel Z Mukhametshina, Michael Schumacher, Silvia Novello, Rafal Dziadziuszko, Wenbo Tang, Laura Clementi, Agnieszka Cseh, Dariusz Kowalski,

de_marinis_1200.55_real_world_study_wclc_poster.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2019

Find information on Boehringer Ingelheim’s activities at WCLC 2019

Related information

NSCLC AFATINIB CLINICAL TRIALS / STUDIES

FOR HEALTHCARE PROFESSIONALS ONLY.